Abstract:This study employs single‐cell transcriptomic analysis to identify subgroups of glioblastoma‐associated macrophages. Spatial transcriptomic analysis reveals the spatial distribution of macrophages within glioblastoma tissue. In vitro experiments demonstrate that inhibition of MS4A4A reduces the immunosuppressive function of M2‐type macrophages. In vivo experiments confirm that inhibition of MS4A4A enhances the response of glioblastoma to PD‐1 immunotherapy. This study provides new theoretical bases and molecular therapeutic targets for the diagnosis and treatment of glioblastoma. Introduction Glioblastoma (GBM) remains a challenging brain tumor to treat, with limited response to PD‐1 immunotherapy due to tumor‐associated macrophages (TAMs), specifically the M2 phenotype. This study explores the potential of MS4A4A (membrane spanning four domains, subfamily A, member 4A) inhibition in driving M2 macrophage polarization toward the M1 phenotype via the ferroptosis pathway to enhance the effectiveness of immunotherapy in GBM. Methods Single‐cell RNA sequencing and spatial transcriptomic analyses were employed to characterize M2 macrophages and MS4A4A expression in GBM. In vitro studies utilizing TAM cultures, flow cytometry, and western blot validations were conducted to assess the impact of MS4A4A on the tumor immune microenvironment and M2 macrophage polarization. In vivo models, including subcutaneous and orthotopic transplantation in mice, were utilized to evaluate the effects of MS4A4A knockout and combined immune checkpoint blockade (ICB) therapy on tumor growth and response to PD‐1 immunotherapy. Results Distinct subsets of GBM‐associated macrophages were identified, with spatial distribution in tumor tissue elucidated. In vivo experiments demonstrated that inhibiting MS4A4A and combining ICB therapy effectively inhibited tumor growth, reshaped the tumor immune microenvironment by reducing M2 TAM infiltration and enhancing CD8+ T‐cell infiltration, ultimately leading to complete tumor eradication. Conclusion MS4A4A inhibition shows promise in converting M2 macrophages to M1 phenotype via ferroptosis, decreasing M2‐TAM infiltration, and enhancing GBM response to PD‐1 immunotherapy. These findings offer a novel approach to developing more effective immunotherapeutic strategies for GBM.

Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application

Therapeutic Potential for Bone Morphogenetic Protein 4 in Human Malignant Glioma

Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells.

BMP4 Reverses Multidrug Resistance Through Modulation of BCL-2 and GDNF in Glioblastoma

Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251.

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures

Nanomedicines Targeting Glioma Stem Cells

The Effect of BMP4 on Multidrug Resistance in Glioblastoma and the Mechanism Study

BMP4 induces a p21-dependent cell state shift in glioblastoma linking mesenchymal transition to senescence

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma

Effects of Adriamycin and Bone Morhogenetic Proteins 4 in Human Brain Glioma Cell Line U251 and Probable Signal Pathway

Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy

Targeted therapies for Glioblastoma multiforme (GBM): State‐of‐the‐art and future prospects

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

BMP4 inhibits glioblastoma invasion by promoting E-cadherin and claudin expression.

Cancer Stem Cells in Glioblastoma—molecular Signaling and Therapeutic Targeting

Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy

Virtual Clinical Trials of BMP4 Differentiation Therapy: Digital Twins to Aid Glioblastoma Trial Design

Significance of Bone Morphogenetic Protein 4 and SMAD 4 in the Diagnosis of Glioma

Polymer nanocarriers for targeted local delivery of agents in treating brain tumors